Physician profile
Kay-Ann Nickeisha Mclean
NPI 1144883232
$7,258.84
in general payments reported to CMS, 2019-2025
21 companies · $2,918 in 2025
The $2,918 reported for 2025 was more than what 99% of General Practice (Registered Nurse) providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.94 · 2023: $1,022 · 2024: $3,303 · 2025: $2,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,159 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,158.90 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,251.31 | 2023-2025 | |
| Madrigal Pharmaceuticals | $847.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $751.15 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $486.63 | 2023-2025 | Entyvio |
| Janssen Biotech, INC. | $361.50 | 2023-2024 | Stelara, Tremfya |
| Regeneron Healthcare Solutions, INC. | $267.44 | 2024-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $241.13 | 2023-2024 | Linzess |
| Gilead Sciences, INC. | $207.83 | 2024-2025 | Livdelzi |
| Genzyme Corporation | $202.03 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $127.62 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $98.85 | 2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $92.88 | 2024 | Tremfya |
| Merck Sharp & Dohme LLC | $86.90 | 2023-2024 | Dificid |
| Aimmune Therapeutics, INC. | $48.49 | 2025 | Zenpep |
| Novo Nordisk INC | $41.73 | 2025 | Wegovy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $40.48 | 2023 | Gimoti |
| Intercept Pharmaceuticals, INC. | $37.39 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $18.96 | 2025 | Iqirvo |
| Lilly USA, LLC | $17.46 | 2024 | Omvoh |
| Organon LLC | $16.08 | 2025 | Hadlima |
| E.R. Squibb & Sons, L.L.C. | $15.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kay-Ann Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.